Takeda | PharmaShots

Takeda’s Pevonedistat Receives the US FDA’s Breakthrough Therapy Designation to Treat Patients with Higher-Risk Myelodysplastic Syndrome

July 31, 2020July 31, 2020Tuba Khan

Shots: The BT designation is based on the final analysis of the Pevonedistat-2001 P-II study assessing pevonedistat + azacitidine vs azacitidine as monothx. [Read More...]

Takeda Collaborates with Carmine for Non-Viral Gene Therapies Worth Up to $900M

July 1, 2020July 1, 2020Tuba Khan

Shots: The two companies signed a research agreement to discover, develop and commercialize transformative non-viral gene therapies for two rare disease targets using [Read More...]

Insights+ Exclusive: COVID-19 Healthcare News Monthly Updates – June 2020

June 30, 2020July 3, 2020Tuba Khan

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 [Read More...]

PharmaShots Weekly Snapshot (Jun 15-19, 2020)

June 22, 2020June 29, 2020Tuba Khan

1. Ultragenyx and Kyowa Kirin’s Crysvita (burosumab) Receive the US FDA’s Approval for the Treatment of Tumor-Induced Osteomalacia Published: Jun 19, 2020 | Tags: [Read More...]

Takeda, Neurocrine, Collaborate, Seven, Neuro Programs, Worth Up to, $2B

Takeda and Neurocrine Collaborate for Seven Neuro Programs Worth Up to $2B

June 17, 2020June 17, 2020Tuba Khan

Shots: Takeda to receive $120M as upfront in cash, ~ $495M as development milestones, and ~$1.4B as commercial milestones along with royalties on [Read More...]

PharmaShots Weekly Snapshot (Jun 08- 12, 2020)

June 15, 2020June 22, 2020Tuba Khan

1. Medtronic Receives CE Mark for MiniMed 780G Insulin Pump to Treat Type 1 Diabetes Published: Jun 11, 2020 | Tags: Medtronic, Receives, [Read More...]

Takeda to Divest OTC and Select Non-core Assets to Celltrion for ~ $278M

June 12, 2020June 12, 2020Tuba Khan

Shots: Takeda has signed an agreement with Celltrion to divest 18 select OTC and prescription pharmaceutical assets exclusively commercialized in the Asia Pacific [Read More...]

Takeda Reports Results of Takhzyro (lanadelumab) in P-III HELP Study for the Prevention of Hereditary Angioedema Attacks

Takeda Signs an Exclusive License and Research Agreement with Debiopharm to Develop Novel Microbiome Therapeutics for the Gastrointestinal Disorders

June 10, 2020June 10, 2020Tuba Khan

Shots: Takeda will screen & optimize compounds derived from Debiopharm’s Debio 1454M program to identify candidates for further development to treat IBD and [Read More...]